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ABSTRACT
Objective To evaluate the protective efficacy of
co-trimoxazole prophylaxis against malaria in HIV
exposed children (uninfected children born to HIV
infected mothers) in Africa.
Design Non-blinded randomised control trial
Setting Tororo district, rural Uganda, an area of high
malaria transmission intensity
Participants 203 breastfeeding HIV exposed infants
enrolled between 6 weeks and 9 months of age
Intervention Co-trimoxazole prophylaxis from enrolment
until cessation of breast feeding and confirmation of
negative HIV status. All children who remained HIV
uninfected (n=185) were then randomised to stop
co-trimoxazole prophylaxis immediately or continue
co-trimoxazole until 2 years old.
Main outcome measure Incidence of malaria, calculated
asthenumberofantimalarialtreatmentsperpersonyear.
Results The incidence of malaria and prevalence of
genotypic mutations associated with antifolate
resistancewere high throughoutthe study. Among the 98
infants randomised to continue co-trimoxazole, 299
malaria cases occurred in 92.28 person years (incidence
3.24 cases/person year). Among the 87 infants
randomised to stop co-trimoxazole, 400 malaria cases
occurredin 71.81personyears(5.57cases/personyear).
Co-trimoxazole prophylaxis yielded a 39% reduction in
malaria incidence, after adjustment for age at
randomisation (incidence rate ratio 0.61 (95% CI 0.46 to
0.81), P=0.001). There were no significant differences in
the incidence of complicated malaria, diarrhoea,
pneumonia, hospitalisations, or deaths between the two
treatment arms.
Conclusions Co-trimoxazole prophylaxis was moderately
protective against malaria in HIV exposed infants when
continued beyond the period of HIV exposure despite the
high prevalence of Plasmodium genotypes associated
with antifolate resistance.
Trial registration Clinical Trials NCT00527800
INTRODUCTION
HIV and malaria are two of the deadliest infectious
diseases, together accounting for more than four mil-
lion deaths annually worldwide and more than a mil-
lion deaths in children aged less than 5 years in sub-
Saharan Africa.
12 Malaria prevention is especially
important in children infected with HIV or exposed
to HIV (uninfected children born to HIV infected
mothers) given the increased susceptibility of these
children to severe illness and death.
3-5 The primary
method of malaria prevention in young children is
the use of bed nets treated with insecticide. However,
thereisnowrenewedinterestinchemoprevention,the
use of antimalarial drugs to prevent disease. One
option for chemoprevention is the use of daily co-
trimoxazole prophylaxis, based on evidence from
observational cohorts of HIV infected children and a
singlerandomisedcontroltrialofHIVuninfectedchil-
drenshowingthatco-trimoxazoleprophylaxisprotects
children from malaria.
6-9
The World Health Organization (WHO) recom-
mends placing all infants of HIV infected mothers on
co-trimoxazole prophylaxis starting at 6 weeks of age
until cessation of breast feeding and exclusion of HIV
infection.
10Thisguidelinestemsfromevidencethatco-
trimoxazole prophylaxis protects HIV infected chil-
dren from common opportunistic infections,
11-13
including malaria.
679 However, there are no studies
on the protective efficacy of co-trimoxazole prophy-
laxis against malaria among HIV exposed, uninfected
infants.MorethantwomillioninfantsareborntoHIV
infected African mothers each year, with more than
90% remaining uninfected throughout breast
feeding.
14-16 To exclude HIV infection in these chil-
dren, HIV DNA testing by polymerase chain reaction
(PCR) is required because of the persistence of mater-
nal HIV antibodies in infant blood until 18 months of
age. However, access to PCR testing remains extre-
mely limited in most resource poor settings, and so
large numbers of HIV exposed children throughout
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until 18 months old, when exclusion of HIV infection
by antibody testing becomes possible.
Weconductedarandomisedclinicaltrialtoexamine
whether prolonged daily co-trimoxazole prophylaxis
beyondtheperiodofbreastfeedingprovidessustained
protective efficacy against malaria in HIV uninfected
children born to HIV infected mothers in an area of
high malaria transmission intensity in rural Uganda.
METHODS
Study setting and enrolment of participants
The study was conducted in Tororo, a rural setting
located in southeastern Uganda, where malaria is
holoendemic and the inoculation rate from insect
bites is 591 infective bites per person year.
17 We used
convenience sampling to enrol a cohort of HIV
exposed infants from the Mother and Child Health
Clinic of Tororo District Hospital and the AIDS Sup-
port Organization (TASO) between August 2007 and
April 2008. Mothers were not enrolled in the study,
and their HIV infection was confirmed by serology
through a national HIV testing programme.
Infants’ eligibility criteria included age 6 weeks to
9months,documentedHIVuninfectedstatusofinfant
andHIVinfectedstatusofmother,currentbreastfeed-
ing, residence within 30 km radius of the study clinic,
parent’s or guardian’s agreement to come to the study
clinic for any febrile episode or other illness and to
avoidmedicationsadministeredoutsidethe studypro-
tocol, absence of active medical problem requiring
inpatient evaluation at the time of screening, and par-
ent’s or guardian’s informed consent. All infant parti-
cipantsunderwentastandardisedclinicalhistoryanda
physicalexaminationatenrolmentincludingthickand
thinbloodsmearsandacompletebloodcount.Inaddi-
tion,allparticipantswereprovidedwithabednettrea-
ted with long lasting insecticide and their parents or
guardians were instructed in its use. Daily co-trimoxa-
zole prophylaxis was prescribed to all infant partici-
pants at enrolment, and to their HIV infected
mothersiftheywerenotalreadytakingco-trimoxazole
in accordance with national guidelines. HIV infected
mothers were advised to exclusively breastfeed their
infants until at least 6 months of age and then to wean
them to alternative feeding when this was acceptable,
safe, feasible, affordable, and sustainable, in accor-
dance with national and WHO guidelines at the time
of the study.
18
Follow up of study participants
Study participants were followed for all their medical
problems in a dedicated study clinic open seven days a
week from8 am to5 pmwith after-hours care available
at the Tororo District Hospital adjacent to the study
clinic. Parents or guardians were encouraged to avoid
usingoutsidemedicationsandtobringtheirinfanttothe
study clinic or hospital any time the child was ill (trans-
portation costs were reimbursed). Children who pre-
sented with new medical problems underwent
standardised medical evaluation. A set of algorithms
wasdevelopedtoguidetreatmentforcommonillnesses.
Drugs with antimalarial activity were avoided for the
treatment of non-malarial illnesses when possible.
Monthlyroutineassessmentsweredoneinthestudy
clinic to ensure adherence to the study protocol, drug
use, and use of the insecticide treated bed net. Adher-
ence to co-trimoxazole prophylaxis was determined
monthly from responses to a validated questionnaire
regarding the number of doses taken in the past three
days and the percentage of doses taken in the past
month. The date of breast feeding cessation was deter-
mined from the monthly visits, where children’s
breastfeeding status and practices were assessed by
asking the mothers how they had been feeding their
childfortheprevioussevendays.Routinephlebotomy
for a complete blood count was performed every
90 days for each participant.
Ateachfollow-upvisit,studycliniciansassessedpar-
ticipants for adverse events according to standardised
criteria based on guidelines from the WHO and
National Institutes of Health. Adverse events were
defined as untoward medical occurrences, following
the guidelines of the International Conference on
Harmonization,
19 and serious adverse events were
defined as experiences resulting in death or life threa-
tening events, inpatient hospitalisation, persistent or
substantial incapacity, or medical or surgical inter-
vention to prevent serious outcomes. Study partici-
pants were withdrawn from the study for permanent
movement out of the study area, if they could not be
located by study staff for >60 consecutive days, with-
drawal of informed consent, inability to adhere to the
study schedule and procedures, or inability to tolerate
study drugs.
Treatment allocation and study drug administration
Six to eight weeks after cessation of breast feeding,
each participant was tested for HIV infection by
DNA PCR. Participants who acquired HIV during
breast feeding were excluded from the study but con-
tinued to be followed up and cared for in the clinic as
part of another study.
ThosewhoremainedHIVuninfectedaftercessation
of breastfeeding were randomised to discontinue co-
trimoxazole prophylaxis immediately or to continue
daily co-trimoxazole prophylaxis until 2 years of age.
A randomisation list was computer generated by an
off-site investigator. Sequentially numbered, sealed
envelopes containing the prophylaxis assignments
were prepared from the randomisation list. The study
nurse assigned prophylaxis numbers sequentially and
allocated co-trimoxazole prophylaxis or no prophy-
laxis by opening the envelope corresponding to the
prophylaxis number. Participants randomised to con-
tinue co-trimoxazole prophylaxis were given a
month’s supply of the drug at each routine visit (every
30 days).
A nurse administered co-trimoxazole syrup
and tablets according to weight based guidelines.
Young children weighing <15 kg were prescribed
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200 mg sulfamethoxazole/5 mL suspension) at the fol-
lowingdoses:2.5mL/dayforchildren≤4kginweight,
5 mL/day for children >4–8 kg, and 10 mL/day for
children >8–15 kg. As children reached 10–15 kg,
they were switched to co-trimoxazole tablets (80 mg
trimethoprim and 400 mg sulfamethoxazole) and
were prescribed one tablet daily thereafter.
Diagnosis and management of malaria
Medical diagnoses were made by medical officers
using predetermined criteria. Participants who pre-
sentedtotheclinicwithadocumentedfever(tympanic
temperature ≥38.0°C) or history of fever in the pre-
vious 24 hours had blood collected by finger prick for
a thick blood smear for malaria. If parasites were
present, malaria was diagnosed regardless of parasite
density. Complicated malaria was diagnosed in parti-
cipants with a malaria diagnosis and either danger
signsorcriteriaforseveremalaria.
20Studyparticipants
≥4monthsoldandweighing≥5kgwithuncomplicated
malaria diagnosed were randomly assigned to receive
either open label artemether-lumefantrine or dihy-
droartemisinin-piperaquine at the time of their first
episode of malaria and received the same treatment
for all subsequent episodes of uncomplicated malaria
diagnosed during the study as part of a nested rando-
mised drug efficacy trial.
21 Children aged <4 months
or weighing <5 kg with uncomplicated malaria and
childrenwithsevereorcomplicatedmalariaweretrea-
ted with standard doses of quinine.
Participants with malaria diagnosed were asked to
return on days 1, 2, 3, 7, 14, 21, 28, and any other day
theywereill.Follow-upevaluationsconsistedofastan-
dardised medical history and physical examination.
Blood was obtained by finger prick for thick blood
smears and storage on filter paper on all follow-up
daysexceptday1.Treatmentoutcomeswereclassified
accordingtoWHOguidelines.
20Outcomesdesignated
as treatment failures included early treatment failures
(complicated malaria or failure to adequately respond
totreatmentondays0–3),lateclinicalfailures(compli-
cated malariaor fever andparasitaemiaon days4–28),
and late parasitological failures (asymptomatic para-
sitaemia on days 7–28).
Diagnosis of diarrhoea and respiratory tract infections
Diarrhoea was included in the analysis if the partici-
pantwasdiagnosedwithacutediarrhoea,chronicdiar-
rhoea, dysentery, or gastroenteritis. Acute diarrhoea
was defined as more than five watery stools a day for
children aged <1 year and more than three watery
stools a day for children aged ≥1 year of age lasting
forlessthantwoweeks.Chronicdiarrhoeawasdefined
by the same criteria as acute diarrhoea but lasting for
two weeks or longer. Dysentery was definedas grossly
bloody or purulent stool by examination or history.
Gastroenteritis was defined as diarrhoea and vomiting
together of less than four days’ duration.
Respiratorytractinfectionswereincludedintheana-
lysis if the participant was diagnosed with pneumonia
orseverepneumonia.Pneumoniawasdefinedasfever
and cough with adventitious lung sounds or respira-
tory distress, or both. Severe pneumonia was defined
as pneumonia with severe respiratory distress requir-
ingchestradiography,hospitalisation,andintravenous
antibiotics. Upper respiratorytract infections were not
included in the analysis.
Laboratory procedures
Before enrolment, all participants were tested for HIV
infection by DNA PCR (Amplicor HIV-1 DNA
PCR Test, version 1.5, Roche, Branchburg NJ, USA)
using dried blood spots collected on filter paper.
Mothers were previously tested at the antenatal clinic
by HIV rapid antibody testing or enzyme linked
immunosorbent assay (ELISA) antibody testing fol-
lowing national HIV testing algorithms.
22 All partici-
pantswereretestedatsix toeightweeksaftercomplete
cessation of breastfeeding with the PCR test, and at
18 months of age with both antibody testing (Deter-
mine Rapid test for HIV-1, Abbott Laboratories,
Abbott Park IL, USA) and PCR assay of dried blood
spots. All positive PCR results were confirmed by
repeat bleeding and testing using quantitative HIV
RNA PCR (Cobas Amplicor HIV-1 RNA Monitor
Test, version 1.5, Roche).
Thick smears were stained with 2% Giemsa stain for
30 minutes, and parasite density was estimated using a
rigorous quality control system previously described.
6
Parasite species was determined on the day that
malaria was diagnosed using nested PCR of 18S
small subunit ribosomal DNA as previously
described.
23 Haemoglobin measurements were made
using a portable spectrophotometer (HemoCue,
Ängelholm, Sweden) on days 0 and 28 of a given
malaria episode or on the day of recurrent malaria.
We randomly selected 148 malaria episodes from
each treatment arm divided equally into four periods
of six months each (December 2007 to May 2008,
June 2008 to November 2008, December 2008 to
May 2009, and June 2009 to November 2009) to test
for markers of antifolate resistance, as previously
described.
24-27 Using filter paper specimens collected
on the day of malaria diagnosis, we tested for the pre-
senceofthreemutationsinthedihydrofolatereductase
gene (dhfr 108N, 51I, and 59R) and two mutations in
the dihydropteroate synthase gene (dhps 437G and
540Q) commonly found in East Africa. Additionally,
we tested for one dhfr mutation (164L) and three dhps
mutations (436S, 581G, and 613S) rarely found in
Africa, but also associated with antifolate resistance.
27
Specimenswereclassifiedaswildtypeor puremutant,
ormixed(bothmutantandwildtypeallelesdetectedin
the same specimen).
Statistical analysis
Data were double entered in Epi-Info, and statistical
analysis was performed with Stata version 10 (Stata,
RESEARCH
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were evaluated based on an intention to treat analysis
includingallparticipantswhowererandomisedtocon-
tinue or discontinue co-trimoxazole prophylaxis.
Malaria incidence was defined as the number of new
episodesofmalariaperpersontimeatrisk.Timeatrisk
included time from the day after randomisation until
each child reached 2 years of age or was withdrawn
from the study, whichever came first. In calculating
the incidence of malaria, episodes of malaria and
time at risk were censored for 14 days after start of
each malaria treatment as children were not at risk
for new episodes of malaria during this period. Using
molecular genotyping, we have shown that over 95%
of malaria episodes occurring more than 14 days after
initiation of antimalarial therapy were due to new
infections.
21
Cumulative risks of developing a first episode of
malaria after randomisation were estimated with the
Kaplan-Meier product limit formula. Data were cen-
sored for patients who were prematurely withdrawn
from the study. Comparison of survival curves was
made using the log rank test. Comparisons of the inci-
dence of malaria, complicated malaria, diarrhoea,
respiratory tract infections, hospitalisations, and mor-
tality were made with negative binomial regression,
with adjustment for age at randomisation. Protective
efficacy was definedusingan incidence rate ratio(inci-
dence of malaria among children continuing co-tri-
moxazole v incidence among those who stopped). We
used generalised estimating equation methods with
exchangeable correlation structure to account for
repeated measures among the same individuals in
comparing the association of co-trimoxazole prophy-
laxis with characteristics of malaria episodes and the
presence of the dhfr and dhps mutations. A P value
<0.05 was considered significant.
RESULTS
Trial profile and baseline characteristics
Atotalof203HIVexposedbreastfeedinginfantswere
enrolled between August 2007 and April 2008 (fig 1).
Ten infants (5%) were withdrawn and eight (4%) sero-
converted to HIV infected status before randomisa-
tion. With cessation of breastfeeding, infants of HIV
infected mothers were no longer considered to be at
risk of acquiring HIV infection. After confirmation of
negative HIV status, 185 infants were randomised
either to continue co-trimoxazole prophylaxis (n=98)
or to stop prophylaxis (n=87), and a total of 170 com-
pleted follow-up (fig 1).
Table 1 shows the participants’ baseline character-
istics. There were no significant differences between
the two study arms in age at randomisation, time at
risk and malaria incidence before randomisation, per-
centage time using the insecticide treated bed net,
adherence to continuing or stopping co-trimoxazole
after randomisation, or percentage of participants liv-
ing in Tororo town (associated with a lower incidence
of malaria compared with living outside of town).
Protective efficacy of co-trimoxazole prophylaxis against
malaria
There were 699 episodes of malaria in total: 299 epi-
sodes among participants randomised to continue co-
trimoxazole prophylaxis and 400 episodes among
those randomised to discontinue co-trimoxazole.
Nineepisodeswerecausedbynon-falciparumspecies:
fiveamongparticipantswhocontinuedco-trimoxazole
prophylaxis(Plasmodiumovalen=3,andPmalariaen=2)
and four among those who stopped co-trimoxazole
after breast feeding (P ovale n=2, P malariae n=1, and P
vivax n=1).
Among the 98 infants randomised to continue co-
trimoxazole, 72 had at least one episode of malaria
Randomised to stop
co-trimoxazole prophylaxis (n=87)
Randomised to continue
co-trimoxazole prophylaxis (n=98)
Children reached 2 years of age (n=80) Children reached 2 years of age (n=90)
HIV exposed breastfeeding children enrolled and given co-trimoxazole prophylaxis (n=203)
Stopped breast feeding (n=195)
Withdrawn before ending breast feeding (n=8):
  Moved >30 km from study clinic (n=6)
  Died (n=1)
  Could not be located for >60 days (n=1)
Died (n=1)
Withdrawn before 2 years of age (n=7):
  Moved >30 km from study clinic (n=4)
  Died (n=1)
  HIV infected at 18 months old† (n=1)
  Unable to comply with study procedures
    (n=1)
Withdrawn before 2 years of age (n=8):
  Moved >30 km from study clinic (n=3)
  Died (n=2)
  Informed consent withdrawn (n=1)
  Could not be located for >60 days (n=1)
  Prophylaxis stopped early (n=1)
* Retested by HIV DNA polymerase chain reaction
† All randomised children were retested at 18 months of age by polymerase chain reaction
Retested for HIV infection* (n=194)
HIV uninfected children eligible for randomisation (n=185)
Seroconverted to HIV infected (n=8)
Died (n=1)
Fig 1 | Participant flow through trial
Table 1 |Baseline characteristics of 185 children at the time of randomisation to continued
co-trimoxazole prophylaxis versus no prophylaxis. Values are numbers (percentages) unless
stated otherwise
Characteristic
Co-trimoxazole prophylaxis
Continued (n=98) Stopped (n=87)
Female 45 (46) 47 (54)
Median (interquartile range) age (months):
At study enrolment 3.2 (2.3–5.7) 3.9 (2.0–6.8)
At stopping breast feeding 7.2 (6.1–10.0) 7.6 (6.8–10.8)
At randomisation 9.6 (8.3–12.4) 10.0 (8.9–13.5)
Incidence* (95% CI) of malaria before randomisation 1.39 (1.08 to 1.76) 1.32 (1.00 to 1.70)
Living in urban area of Tororo town 19 (19) 16 (18)
*No of episodes/person year
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87childrenrandomisedtostopco-trimoxazole,78had
atleastoneepisodeofmalariaduringfollow-up(cumu-
lative risk 93.4%). Figure 2 shows that there was a sig-
nificant difference in the malaria-free survival curves
between the two study arms (P=0.003).
From the time of randomisation until each partici-
pant reached 2 years of age, the incidence of malaria
was 3.24 episodes/person year (95% confidence inter-
val2.89to3.63)amongparticipantswhocontinuedco-
trimoxazole prophylaxis and 5.57 episodes/person
year (5.04 to 6.14) among participants who stopped
prophylaxis, representing a 39% lower risk of malaria
for the children who continued taking co-trimoxazole
(incidencerateratio0.61(95%confidenceinterval0.46
to 0.81, P=0.001) (fig 3).
In investigating whether the protective effect of co-
trimoxazolechangedovertime,wefoundtherewasno
difference in the protective efficacy during the first
30 days after randomisation (incidence rate ratio 0.83
(0.45 to 1.53), P=0.55) compared with the period from
30daysafterrandomisationto2yearsofage(incidence
rate ratio 0.59 (0.44 to 0.80), P<0.001) (P=0.30 for
interaction term). Apart from the period immediately
after randomisation, the difference in the incidence of
malaria between those children taking co-trimoxazole
prophylaxis and those who stopped co-trimoxazole
was constant with increasing time after randomisation
and with increasing age (fig 4).
There were three episodes of complicated malaria
among the participants randomised to continue co-tri-
moxazole prophylaxis and four episodes among those
randomised to stop co-trimoxazole (incidence rate
ratio=0.59, P=0.50). Eight hospitalisations and two
deaths occurred among the children randomised to
continue co-trimoxazole, compared with four hospita-
lisations and one death among those randomised to
stopco-trimoxazole(P=0.79andP=0.61,respectively).
Protective efficacy of co-trimoxazole prophylaxis against
diarrhoea and respiratory tract infections
From the date of randomisation to 2 years of age, the
children randomised to continue co-trimoxazole had
189 episodes of diarrhoea and 33 episodes of respira-
tory tract infection, compared with 170 episodes of
diarrhoeaand20episodesofrespiratorytractinfection
among those randomised to stop co-trimoxazole.
Children not taking co-trimoxazole had a diarrhoea
incidence of 1.96 episodes/person year (95% confi-
dence interval 1.67 to 2.27), whereas those taking co-
trimoxazole prophylaxis had a diarrhoea incidence of
1.83 episodes/person year (1.57 to 2.10), resulting in a
9% protective efficacy that was not significant (inci-
dence rate ratio 0.91, P=0.48) (fig 3). The incidence of
respiratory tract infections was 0.32 episodes/person
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Fig 2 | Time to first malaria episode among 185 HIV uninfected
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moxazole and 0.23 episodes/person year (0.14 to
0.36) for those not taking co-trimoxazole, resulting in
a 37% increased risk of respiratory tract infections for
continued co-trimoxazole, though not statistically sig-
nificant (incidence rate ratio 1.37, P=0.27) (fig 3).
Secondary outcomes and adverse events
At the time of their presentation with malaria, partici-
pants randomised to continue taking co-trimoxazole
hadsignificantlylowerbaselinetemperatureandpara-
site density than the group who stopped co-trimoxa-
zole (table 2). They also showed a non-significant
trend of increased clearance of parasites on days 2
and 3 after malaria diagnosis (table 2). Furthermore,
the risk of treatment failure (recurrent parasitaemia by
day 28 after diagnosis and treatment) was significantly
lower among the children who continued co-trimoxa-
zole (19% v 32%, P=0.006).
Therewasnodifferencebetweenthetwostudyarms
in either the median haemoglobin concentration at
day 0 of each malaria episode or the mean change in
haemoglobinconcentrationbetweenday 0 and day28
of malaria follow-up. Median neutrophil values and
the prevalence of neutropenia from routine complete
blood counts were not significantly different between
the two study arms. There were no episodes of skin
reactions, allergic drug reactions, or other unexpected
adverse events in either study arm.
Markers of antifolate resistance
Of the 148 malaria episodes randomly selected from
each study arm to test for markers of antifolate resis-
tance, we were able to establish genotypes in 139 epi-
sodes (94%) from the continued co-trimoxazole arm
and 142 episodes (96%) from the discontinued co-tri-
moxazole arm. Table 3 shows the prevalence of sam-
ples with either mixed (both wild type and mutant
alleles present) or pure mutant genotypes detected.
There was little difference in genotype prevalence
between study arms, and most of the mutations
detected were in the pure mutant form. There were
relatively few mixed mutant infections, with the high-
est prevalence of mixed infections found at dhfr 59R,
where there were 4.3% mixed infections among epi-
sodes in the continued co-trimoxazole arm and 6.3%
mixed infections among episodes in the discontinued
co-trimoxazole arm.
The dhfr/dhps quintuple mutant, composed of dhfr
51I, 59R, and 108N and dhps 437G and 540Q muta-
tions,wasfoundin95%ofepisodesfromchildrenwho
continued co-trimoxazole and 91% of episodes from
children who discontinued co-trimoxazole (relative
risk 1.05 (0.98 to 1.13), P=0.17). When examined in
four intervals of six months each, from the earliest
date of randomisation (December 2007) to the date
when the last participant reached 2 years of age
(November 2009), the prevalence of the dhfr/dhps
quintuple mutant among malaria episodes in the chil-
dren who continued to take co-trimoxazole was 94%,
89%, 100%, and 97% for each interval, and its preva-
lence among the children who stopped taking co-tri-
moxazole was 89%, 95%, 94%, and 86%. None of the
differencesbetweenthestudyarmsintheprevalenceof
the dhfr/dhps quintuple mutant was significant.
DISCUSSION
Principal findings
In this study, we found that co-trimoxazole prophy-
laxis was moderately protective against malaria in
HIV exposed children when continued beyond the
period of HIV exposure until 2 years of age in an
area of high malaria transmission intensity and high
prevalence of resistance to antifolate antimalarial
drugs. The protective efficacy of co-trimoxazole was
lower in the first month after randomisation, but
there was not enough power to detect a significant dif-
ference between the first month after randomisation
and the remainder of the time at risk. Nevertheless,
this may indicate a transitional period when children
whohadstoppedtakingprophylaxiswerestillpartially
protected.Beyondthefirstmonthafterrandomisation,
the protective efficacy of co-trimoxazole against
malaria was consistent and did not diminish with time
or increasing age. Participants who continued co-tri-
moxazole prophylaxis also had lower parasite densi-
ties at the time of malaria diagnosis and a lower
prevalence of recurrent parasitaemia by day 28 after
diagnosis, suggesting that co-trimoxazole prophylaxis
still provided benefit even when children did acquire
malaria.
Comparison with other studies
The protective efficacy of co-trimoxazole prophylaxis
againstmalariainourtrialwassubstantiallylowerthan
Table 2 |Characteristics of the 699 malaria episodes among 185 children randomised to
continued co-trimoxazole prophylaxis versus no prophylaxis. Values are numbers
(percentages) of episodes unless stated otherwise
Characteristic
Co-trimoxazole
prophylaxis
P value of
difference
Continued
(n=299)
Stopped
(n=400)
Mean (SD) baseline temperature (°C) 38.2 (1.0) 38.4 (1.1) 0.05
Geometric mean baseline parasite density (parasites/μL) 13 473 21 108 0.02
Gametocytes present at baseline 24 (8) 22 (6) 0.27
Mean (SD) baseline haemoglobin concentration (g/L) 101 (16) 100 (15) 0.37
Malaria treatment regimen:
Artemether-lumefantrine 163 (55) 208 (52) —
Dihydroartemisinin-piperaquine 133 (44) 184 (46) 0.35
Quinine, uncomplicated malaria 0 4 (1) —
Quinine, complicated malaria 3 (1) 4 (1) —
Positive blood smear after treatment:
Day 2 26 (9) 48 (12) 0.14
D a y3 1( 0 . 3 ) 8( 2 ) 0 . 0 7
Treatment failure* 57 (19) 126 (32) 0.006
Mean (SD) haemoglobin recovery† (g/L) 0.56 (1.72) 0.57 (1.57) 0.94
*Early treatment failure, late clinical failure, or late parasitological failure according to 28 day WHO outcome
classification system.
†Change in haemoglobin from day 0 to day 28 or to day of treatment failure.
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trolled trial in Mali showed that co-trimoxazole pro-
phylaxis had a 99.5% protective efficacy against
episodes of clinical malaria and 97% efficacy against
infection.
8 However, the Mali study enrolled older
children (5–15 years old), had a three month follow-
up period, and did not test the HIV status of the chil-
drenortheirmothers,thoughtheoverallprevalenceof
HIV infection in the Mali study region was <2% com-
paredwith6%–7%ineasternUganda.
28Moreover,sul-
fadoxine-pyrimethamine, a common antifolate
antimalarialdrug,wasquiteefficaciousagainstmalaria
in most of western Africa at that time, although anti-
folateresistanceisnowemerging.
2930Anobservational
study in Tororo, Uganda, showed an 80% decrease in
the incidence of malaria among HIV infected adults
and children, as well as among the uninfected mem-
bers of their households, after implementation of co-
trimoxazole prophylaxis.
79 A prospective parallel
cohort study in Kampala, Uganda, also showed an
80% protective efficacy of co-trimoxazole prophylaxis
against malaria among HIV infected children com-
pared with HIV uninfected children not taking co-
trimoxazole.
6
The lower protective efficacy of co-trimoxazole
observed in our study may be due to an improved
study design compared with most of the other studies
(randomisedtrialvobservationalstudy),butitwasalso
probably influenced by differences in malaria trans-
mission intensity, participants’ HIV status and ages,
and prevalence of plasmodial antifolate resistance
mutations.
Studies of malaria chemoprophylaxis have been
attempted with other drugs, including chloroquine,
pyrimethamine and dapsone, chlorproguanil, and ato-
vaquone and proguanil.
31-36 Despite positive results
fromsome ofthesestudies,routinechemoprophylaxis
for malaria has never been widely implemented
because of logistical and economic constraints, and
theconcernforreboundofmalariaincidenceafterces-
sation of chemoprophylaxis. Co-trimoxazole prophy-
laxis may have a logistical advantage over other
antimalarial prophylactic drugs since it is already in
widespread use among HIV infected and HIV
exposed patients in many countries, though the issue
of rebound malaria after cessation needs to be investi-
gated.
The protective efficacy of daily co-trimoxazole pro-
phylaxis against malaria in our study was comparable
to that reported in trials of the RTS,S/AS01 malaria
vaccine and intermittent preventive therapy in infants
(IPTi).
37-42 The IPTi Consortium has completed six
clinical trials investigating the use of such therapy
with sulfadoxine-pyrimethamine in different settings
and showed an average protective efficacy of 30%
with three trials, as well as reducing anaemia.
40 The
IPTi trials differ from our trial in that a lower percen-
tage of participants used bed nets, the risk of malaria
was substantially lower, and the efficacy of sulfadox-
ine-pyrimethamine treatment for uncomplicated
malaria was greater than 70%. It is likely that the pro-
tectiveefficacy ofintermittent preventivetherapywith
sulfadoxine-pyrimethaminewilldecreasewithincreas-
ing antifolate resistance, and a replacement drug has
not yet been firmly established.
43 In our trial co-tri-
moxazole prophylaxis showed a protective efficacy
againstmalaria of 39%,even in the settingof highanti-
folateresistanceandhighmalariariskinTororo.How-
ever,thislevel of protectionfrom malariacomesat the
expense of the increased potential for adverse events,
cost, and logistical difficultiesof providing daily co-tri-
moxazole compared with intermittent sulfadoxine-
pyrimethamine prescribed at the time of childhood
vaccinations.
Antifolate resistance and secondary outcomes
Because of in vitro evidence of cross resistance to co-
trimoxazole and sulfadoxine-pyrimethamine,
4445
scientists have been concerned that the widespread
use of co-trimoxazole prophylaxis will result in an
increased prevalence of sulfadoxine-pyrimethamine
resistant parasites.
1446 Recent studies in Tororo and
Kampala,Uganda,ofHIVinfectedchildrenandadults
taking daily co-trimoxazole prophylaxis have found
no association between co-trimoxazole use and
increased prevalence of mutations conferring anti-
folate resistance.
4748 Both studies were limited by a
high baseline level of antifolate resistant genotypes
and relatively small numbers. In our study, the preva-
lence of the dhfr/dhps quintuple mutant was similar in
the two treatment arms, but our ability to detect an
association between co-trimoxazole use and the dhfr/
dhps quintuple mutant was limited by the virtual
saturationofthequintuplemutantintheparasitepopu-
lation around Tororo. Indeed, to our knowledge, the
overall prevalence of the dhfr/dhps quintuple mutant
in our study is the highest yet reported in Africa.
Although the dhfr/dhps quintuple mutant has been
shown to be related to the failure of sulfadoxine-pyri-
methamine therapy for uncomplicated malaria,
254950
Table 3 |Prevalence of molecular markers of antifolate
resistance in 281 episodes of malaria* among 185 children
randomised to continued co-trimoxazole prophylaxis versus
no prophylaxis. Values are numbers (percentages) of
episodes
Co-trimoxazole prophylaxis
Continued (n=139) Stopped (n=142)
Dihydrofolate reductase gene (dhfr)
Ile-51 (51I) 139 (100) 139 (98)
Arg-59 (59R) 132 (95) 131 (92)
Asn-108 (108N) 139 (100) 142 (100)
Leu-164 (164L) 1 (0.7) 1 (0.7)
Dihydropteroate synthase gene (dhps)
Ala-436 (436S) 2 (1.4) 2 (1.4)
Gly-437 (437G) 139 (100) 140 (99)
Glu-540 (540Q) 139 (100) 141 (99)
Gly-581 (581G) 0 0
Ser-613 (613S) 0 0
*Episodes in which Plasmodium falciparum genotypes could be
established, from a total of 296 randomly selected episodes.
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cacyofco-trimoxazoleprophylaxisagainstmalariahas
yet to be determined.
HIV exposed children experience increased mor-
bidityandmortalityintheirfirstyearsoflifecompared
with HIV uninfected children born to uninfected
mothers.
355152 The reasons for these poor outcomes
among HIV exposed children have been clearly
postulated
5354 and may explain why co-trimoxazole
prophylaxis in this population could provide protec-
tion against serious bacterial and parasitic infections.
However, although co-trimoxazole prophylaxis was
protective against malaria in our cohort, we detected
no differences between the two study arms in the rates
of either diarrhoea or respiratory tract infections, two
common and potentially fatal infectious syndromes
associated with HIV infection. The question of
whether the benefits of co-trimoxazole prophylaxis
among HIV exposed infants who remain HIV unin-
fected outweigh the risks has yet to be clearly deli-
neated.
Conclusions and policy implications
Our data add to the growing number of malaria che-
moprevention trials, which are trying to discern the
best drug, dose, treatment frequency, and treatment
durationforchildrenlivinginareasofdifferingmalaria
transmission intensities. The primary relevance of our
findings is that co-trimoxazole prophylaxis afforded
significant protection against malaria in a setting of
highly endemic and highly resistant malaria. Cur-
rently, co-trimoxazole is used as prophylaxis in HIV
exposed children to prevent opportunistic infections
such as toxoplasmosis and pneumocystis. Given the
increasing interest in chemoprevention of malaria, we
looked at continuing co-trimoxazole prophylaxis
among those children who did not seroconvert during
breast feeding, and we found that continuing co-tri-
moxazole helps to prevent malaria in this population.
Ourstudyalso providesinsightinto providingmalaria
chemoprevention to all children, regardless of HIV
status or exposure.
It is premature to conclude whether co-trimoxazole
should be recommended for HIV exposed children
testing HIV negative after cessation of breast feeding.
Differences in malaria transmission intensity and pre-
valence of antifolate resistance could affect the protec-
tive efficacy of co-trimoxazole prophylaxis at different
sites. Furthermore, questions remain over the effect of
co-trimoxazole use on the continued development of
antifolate resistance and prevention of acquisition of
natural antimalarial immunity, which may result in
anincreasedreboundincidenceofmalariauponcessa-
tion of prophylaxis. To help answer some of these
questions, we are following our cohort to 5 years of
age to examine the continued protective efficacy of
co-trimoxazole against malaria and to evaluate
rebound effects after withdrawal of co-trimoxazole.
The results of this and other studies
55 should better
inform the use of co-trimoxazole prophylaxis in HIV
exposed infants in areas with endemic malaria.
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